Chemomab Therapeutics (NASDAQ:CMMB) versus Immunome (NASDAQ:IMNM) Head-To-Head Survey

Chemomab Therapeutics (NASDAQ:CMMB) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Chemomab Therapeutics and Immunome, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1	1	1	0	2.00
Immunome	1	0	10	0	2.82

Chemomab Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 1,454.53%. Immunome has a consensus target price of $33.45, suggesting a potential upside of 47.18%. Given Chemomab Therapeutics’ higher possible upside, research analysts clearly believe Chemomab Therapeutics is more favorable than Immunome.

Insider & Institutional Ownership

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Chemomab Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Immunome has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Profitability

This table compares Chemomab Therapeutics and Immunome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-103.85%	-90.44%
Immunome	N/A	-57.61%	-52.39%

Valuation and Earnings

This table compares Chemomab Therapeutics and Immunome”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99 million	($2.56)	-0.63
Immunome	$6.94 million	370.92	-$212.39 million	($2.42)	-9.39

Chemomab Therapeutics has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Immunome beats Chemomab Therapeutics on 7 of the 12 factors compared between the two stocks.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.